"FDA approves Neurelis’ nasal spray for seizures" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in ...

allergy and critical care at the FDA's Center for Drug Evaluation and Research (CDER). "The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis.

The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...

Please provide your email address to receive an email when new articles are posted on . Atzumi is the first dihydroergotamine-based nasal powder approved for migraine treatment in adults.

The FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, Satsuma Pharmaceuticals announced Wednesday. The product is the only ...